Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report

Intravenous (i.v.) prostacyclin is the cornerstone treatment in high‐risk pulmonary arterial hypertension (PAH) patients. Selexipag is an orally available prostacyclin receptor agonist. Limited data are available regarding the feasibility of transitioning from i.v. epoprostenol to selexipag. A 50‐ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexandre, André, Furtado, Inês, Carvalho, Luísa, Gonçalves, Fabienne, Melo, Alzira, Alves, Joana, Santos, Mário, Reis, Abílio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375174/
https://www.ncbi.nlm.nih.gov/pubmed/37336527
http://dx.doi.org/10.1002/ehf2.14428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375174/
https://www.ncbi.nlm.nih.gov/pubmed/37336527
http://dx.doi.org/10.1002/ehf2.14428

Ejemplares similares